| Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies R Benjamin, C Graham, D Yallop, A Jozwik, OC Mirci-Danicar, G Lucchini, ... The Lancet 396 (10266), 1885-1894, 2020 | 260 | 2020 |
| Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer H Liu, C Zang, A Emde, MD Planas-Silva, M Rosche, A Kühnl, CO Schulz, ... European journal of pharmacology 591 (1-3), 43-51, 2008 | 157 | 2008 |
| The role of microRNA-196a and microRNA-196b as ERG regulators in acute myeloid leukemia and acute T-lymphoblastic leukemia E Coskun, EK von der Heide, C Schlee, A Kühnl, N Gökbuget, D Hoelzer, ... Leukemia research 35 (2), 208-213, 2011 | 127 | 2011 |
| Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experience V Shah, TK Ko, M Zuckerman, J Vidler, S Sharif, V Mehra, S Gandhi, ... British Journal of Haematology 190 (5), e279, 2020 | 120 | 2020 |
| Antileukemic activity of the HSP70 inhibitor pifithrin-μ in acute leukemia M Kaiser, A Kühnl, J Reins, S Fischer, J Ortiz-Tanchez, C Schlee, ... Blood cancer journal 1 (7), e28-e28, 2011 | 84 | 2011 |
| Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia A Kühnl, N Gökbuget, M Kaiser, C Schlee, A Stroux, T Burmeister, ... Blood, The Journal of the American Society of Hematology 118 (24), 6362-6367, 2011 | 79 | 2011 |
| High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia A Kühnl, N Gökbuget, A Stroux, T Burmeister, M Neumann, S Heesch, ... Blood, The Journal of the American Society of Hematology 115 (18), 3737-3744, 2010 | 73 | 2010 |
| A national service for delivering CD19 CAR‐T in large B‐cell lymphoma–The UK real‐world experience A Kuhnl, C Roddie, AA Kirkwood, E Tholouli, T Menne, A Patel, C Besley, ... British Journal of Haematology 198 (3), 492-502, 2022 | 69 | 2022 |
| Molecular markers in acute myeloid leukaemia A Kühnl, D Grimwade International journal of hematology 96, 153-163, 2012 | 66 | 2012 |
| Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia A Kühnl, PJM Valk, MA Sanders, A Ivey, RK Hills, KI Mills, RE Gale, ... Blood, The Journal of the American Society of Hematology 125 (19), 2985-2994, 2015 | 57 | 2015 |
| BAALC-associated gene expression profiles define IGFBP7 as a novel molecular marker in acute leukemia S Heesch, C Schlee, M Neumann, A Stroux, A Kühnl, S Schwartz, ... Leukemia 24 (8), 1429-1436, 2010 | 54 | 2010 |
| Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma A Kuhnl, C Roddie, AA Kirkwood, T Menne, M Cuadrado, MAV Marzolini, ... Blood advances 6 (1), 321, 2022 | 48 | 2022 |
| Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular … A Kühnl, D Cunningham, N Counsell, EA Hawkes, W Qian, P Smith, ... Annals of Oncology 28 (7), 1540-1546, 2017 | 48 | 2017 |
| High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia A Kühnl, M Kaiser, M Neumann, L Fransecky, S Heesch, M Radmacher, ... Leukemia research 35 (12), 1585-1590, 2011 | 47 | 2011 |
| UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a … R Benjamin, N Jain, MV Maus, N Boissel, C Graham, A Jozwik, D Yallop, ... The Lancet Haematology 9 (11), e833-e843, 2022 | 44 | 2022 |
| Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma C Roddie, L Neill, W Osborne, S Iyengar, E Tholouli, D Irvine, S Chaganti, ... Blood Advances 7 (12), 2872-2883, 2023 | 42 | 2023 |
| Real-world data of high-grade lymphoma patients treated with CD19 CAR-T in England A Kuhnl, C Roddie, N Martinez-Cibrian, TF Menne, K Linton, S Lugthart, ... Blood 134, 767, 2019 | 39 | 2019 |
| Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL M Northend, W Wilson, W Osborne, CP Fox, AJ Davies, D El-Sharkawi, ... Blood advances 6 (9), 2920-2926, 2022 | 22 | 2022 |
| CAR T in patients with large B‐cell lymphoma not fit for autologous transplant A Kuhnl, AA Kirkwood, C Roddie, T Menne, E Tholouli, A Bloor, C Besley, ... British Journal of Haematology 202 (1), 65-73, 2023 | 11 | 2023 |
| Diagnosis and treatment of maternal acute myeloid leukemia during pregnancy imitating HELLP syndrome DM Biener, G Gossing, A Kuehnl, M Cremer, JW Dudenhausen Walter de Gruyter 37 (6), 713-714, 2009 | 11 | 2009 |
